3.58

8.21% -0.32

Rezolute Inc (RZLT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rezolute Inc stock is traded at $3.58, with a volume of 1.40M. It is down -8.21% in the last 24 hours and down -10.05% over the past month. Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Previous Close:

$3.90

Open:

$3.9

24h Volume:

1.40M

Relative Volume:

0.70

Market Cap:

$346.27M

Revenue:

Net Income/Loss:

$-81.49M

P/E Ratio:

-4.4252

EPS:

-0.809

Net Cash Flow:

$-73.48M

1W Performance:

-26.49%

1M Performance:

-10.05%

6M Performance:

+1.13%

1Y Performance:

-59.64%

1-Day Range:

$3.56

$3.99

1-Week Range:

$3.56

$4.91

52-Week Range:

$1.07

$11.46

Rezolute Inc Stock (RZLT) Company Profile

Name

Rezolute Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

650-206-4507

Address

275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

RZLT's Discussions on Twitter

Compare RZLT vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RZLT Rezolute Inc	3.58	346.27M	0	-81.49M	-73.48M	-0.809
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Rezolute Inc Stock (RZLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-30-26	Initiated	Lake Street	Buy
Sep-29-26	Upgrade	Craig Hallum	Hold → Buy
Jun-03-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform
Mar-25-26	Upgrade	Wedbush	Neutral → Outperform
Dec-11-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-11-25	Downgrade	Craig Hallum	Buy → Hold
Dec-11-25	Downgrade	Wedbush	Outperform → Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Aug-27-24	Initiated	Guggenheim	Buy
Jul-17-24	Initiated	BTIG Research	Buy
Jun-04-24	Initiated	Craig Hallum	Buy
Apr-09-24	Initiated	Maxim Group	Buy
Aug-02-22	Resumed	Canaccord Genuity	Buy
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight
Sep-08-21	Initiated	ROTH Capital	Buy
May-27-21	Initiated	Oppenheimer	Outperform
May-25-21	Initiated	H.C. Wainwright	Buy

View All

Rezolute Inc Stock (RZLT) Latest News

Oct 05, 2026

A December 2 shareholder vote could expand Rezolute (RZLT)'s authorized common shares. - Stock Titan

Oct 05, 2026

Sep 11, 2026

Rezolute, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView

Sep 11, 2026

Sep 10, 2026

Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset - Seeking Alpha

Sep 10, 2026

Sep 09, 2026

Rezolute (RZLT) FDA Review Highlights Uncertain Path Amid Cash-F - GuruFocus

Sep 09, 2026

Rezolute says late-stage trial data for lead asset remains under FDA review - TradingView

Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Nigeria

Sep 09, 2026

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint - Yahoo Finance

Sep 09, 2026

Rezolute (RZLT) Updates FDA Review of Phase 3 Data Amid Unprofitable Status - GuruFocus

Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Canada

Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data - investing.com

Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com India

Sep 09, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism - The Manila Times

Sep 09, 2026

Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com UK

Sep 09, 2026

RZLT Q4'26 Earnings: EPS estimate is (0.15) USD - TradingView

Sep 09, 2026

FDA is still reviewing Rezolute’s experimental drug. No timeline is set. - Stock Titan

Sep 09, 2026

Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Diagonal Spread Trade - vinanet.vn

Aug 29, 2026

Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Insider Sentiment - dars.gov.et

Aug 29, 2026

Aug 25, 2026

Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aug 25, 2026

Aug 22, 2026

Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - simplywall.st

Aug 22, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus

Aug 20, 2026

Aug 19, 2026

Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 19, 2026

Aug 17, 2026

Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 17, 2026

Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT - MarketBeat

Aug 17, 2026

Aug 14, 2026

Rezolute Stock Price Forecast. Should You Buy RZLT? - StockInvest.us

Aug 14, 2026

Balyasny reports 4.84% Rezolute (RZLT) stake in Schedule 13G/A - Stock Titan

Aug 14, 2026